Douglas T. Dieterich, M.D.

Douglas T. Dieterich, M.D., is currently Professor of Medicine in the Division of Hepatology and also Director of Continuing Medical Education in the Department of Medicine at Mount Sinai School of Medicine, New York, N.Y. He has a triple appointment in the divisions of Liver Disease, Gastroenterology, and Infectious Diseases.

Dr. Dieterich graduated from Yale University in New Haven, Conn., and received his Doctorate of Medicine from New York University, School of Medicine in N.Y. He completed his internship and residency in Internal Medicine at the Bellevue Hospital Center in New York, N.Y., where he was also a fellow in the Division of Gastroenterology. Following this, he became Clinical Assistant Professor of Medicine and then a Clinical Associate Professor of Medicine, both at New York University.

Dr. Dieterich is an investigator for several ongoing studies evaluating the safety and efficacy of various antiviral treatment regimens for chronic hepatitis B and C.

Dr. Dieterich is a member of many professional societies and is a fellow of both the American College of Physicians and the American College of Gastroenterology. He has served on several committees of the AIDS Clinical Trials Group at the National Institutes of Health (NIH), including the Steering Committee of the Opportunistic Infections Core Committee and the Cytomegalovirus (CMV) Committee. He was Chair and Co-Chair, respectively, of the Enteric Parasites Committee and the Protozoan Committee. He also served on the NIH Study Sections for CMV and cryptosporidiosis.

Widely published, Dr. Dieterich is the author of numerous journal articles, abstracts, and book chapters on viral hepatitis and AIDS-associated infections of the gastrointestinal tract and liver.

Disclosures

Douglas T. Dieterich, M.D., has received grants/research support, serves on the Speakers' Bureau, and is also a consultant for Bristol-Myers Squibb, Gilead Sciences, Idenix Pharmaceuticals, Roche Pharmaceuticals, and Schering-Plough. Dr. Dieterich has also disclosed that he plans to discuss investigational and/or unlabeled uses of products.